Abstract
Objective: To investigate the effect of oxaliplatin combined with tiggio in the treatment of advanced biliary tract tumors. Methods: The research period was from November 2019 to November 2020. 80 patients with advanced biliary tumor disease were enrolled. They were divided into groups according to the order of admission, with 40 cases in each group. The control group received oxaliplatin combined with gemcitabine, and the experimental group received oxaliplatin combined with tiggio. Incidence of adverse reactions, time to disease progression, survival time and clinical efficacy were checked and assessed. Results: Compared with the incidence of adverse reaction of the experimental group, which was 5.00% (2/40), the incidence of adverse reaction of the control group was 25.00% (10/40). The chi-square value = 6.2745, p-value = 0.0122. The time to progression and survival time of patients in the experimental group were shorter than those of the control group, with significant differences between the groups (p<0.05); the clinical efficacy of the experimental group and the control group were 97.50% (39/40) and 77.50% (31/ 40) respectively, the comparative chi-square value = 7.3143, p-value = 0.0068. Conclusion: The combined treatment of oxaliplatin and Tiggio in the treatment of advanced biliary tract tumors has higher safety and reduces the incidence of adverse reactions.